Anavex May Have Just Become a Target for Biogen and Eli Lilly

Anavex Life Sciences Corp. (NASDAQ:AVXL) may have just emerged as a significant player in the Alzheimer’s drug market. The clinical-stage biotech company specializes in the development of treatments for currently incurable diseases. It has stumbled upon AVANEX 3-71 which is a drug candidate that may have significant potential for reduction of synaptic loss, amyloid, and tau pathologies and neuroinflammation associated with the neuro-degenerative disease.

Back to news